NPH16 is an orally active PD-1/PD-L1 inhibitor with an IC50 of 2.24 nM. It promotes apoptosis in HepG2 cells and demonstrates outstanding antitumor efficacy and favorable pharmacokinetic properties in vivo. NPH16 is applicable for liver cancer research.
Target:
PD-1/PD-L1
* VAT and and shipping costs not included. Errors and price changes excepted
